Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.58% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Dec 31, 2025
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-26-007497General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
14.11% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
65.19% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
2.23% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
81.77% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
13.51% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
35.54% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.38% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.97%
- Current
- 1.58%
- Delta
- 0.61%
- Previous
- 26.03%
- Current
- 14.11%
- Delta
- -11.92%
- Previous
- 149.35%
- Current
- 65.19%
- Delta
- -84.15%
- Previous
- 6.04%
- Current
- 2.23%
- Delta
- -3.81%
- Previous
- 84.21%
- Current
- 81.77%
- Delta
- -2.44%
- Previous
- 29.46%
- Current
- 13.51%
- Delta
- -15.96%
- Previous
- 28.73%
- Current
- 35.54%
- Delta
- 6.81%
- Previous
- 8.66%
- Current
- 9.38%
- Delta
- 0.71%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Analogous To · ALNY state analogue 2 →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_INCREASED →Transitioned To · ALNY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.